Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Schram, Alison M., Odintsov, Igor, Espinosa-Cotton, Madelyn, Khodos, Inna, Sisso, Whitney J., Mattar, Marissa S., Lui, Allan J.W., Vojnic, Morana, Shameem, Sara H., Chauhan, Thrusha, Torrisi, Jean, Ford, Jim, O'Connor, Marie N., Geuijen, Cecile A.W., Schackmann, Ron C.J., Lammerts van Bueren, Jeroen J., Wasserman, Ernesto, de Stanchina, Elisa, O'Reilly, Eileen M., Ladanyi, Marc, Drilon, Alexander, Somwar, Romel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394398/
https://www.ncbi.nlm.nih.gov/pubmed/35135829
http://dx.doi.org/10.1158/2159-8290.CD-21-1119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394398/
https://www.ncbi.nlm.nih.gov/pubmed/35135829
http://dx.doi.org/10.1158/2159-8290.CD-21-1119

Ejemplares similares